Effect of vildagliptin on hepatic steatosis.

ABSTRACT:

Context

Although dipeptidyl-peptidase-4 inhibitors exert their major action via an incretin mechanism, a favorable effect of vildagliptin on lipid metabolism remains unexplained.

Objective

The objective was to examine hepatic triglyceride levels and insulin sensitivity on vildagliptin.

Design

This was a 6-month, randomized, double-blind, placebo-controlled trial.

Setting

This was an outpatient study at a university clinical research center.

Patients

Individuals with type 2 diabetes (n = 44) and glycated hemoglobin ≤ 7.6% on stable metformin therapy were included.

Intervention

Intervention was vildagliptin 50 mg twice a day or placebo over 6 months.

Main outcome measures

Main outcome measures were hepatic triglyceride levels and insulin sens

SUBMITTER: Macauley M 

PROVIDER: S-EPMC4399299 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature